Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 7, 2003, Pages 3167-3176

  Crawford, Bronwyn A L ^a,b   Liu, Peter Y ^a   Kean, Mary T ^a,b   Bleasel, Jane F ^a,b   Handelsman, David J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; NANDROLONE DECANOATE; PREDNISOLONE; SEX HORMONE BINDING GLOBULIN; STEROID; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BEHAVIOR DISORDER; BONE DENSITY; BONE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; DYNAMOMETRY; HUMAN; IMMUNOPATHOLOGY; ISOKINETIC EXERCISE; KNEE FUNCTION; LIPIDOSIS; LONG TERM EXPOSURE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE STRENGTH; OBESITY; OSTEOLYSIS; POLYCYTHEMIA; PRIORITY JOURNAL; PROSTATE DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SLEEP APNEA SYNDROME; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEROID THERAPY; TESTOSTERONE BLOOD LEVEL;

ANABOLIC AGENTS; BONE DENSITY; DRUG INTERACTIONS; GLUCOCORTICOIDS; GONADAL STEROID HORMONES; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; NANDROLONE; PLACEBOS; PREDNISONE; QUALITY OF LIFE; QUESTIONNAIRES; TESTOSTERONE;

EID: 0037622805     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021827     Document Type: Article

References (68)

1. Walsh LJ, Wong CA, Pringle M, Tattersfield AE 1996 Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344-346
2. Van Staa T, Leufkens H, Abenhaim L, Abenhaim L, Begaud B, Zhang B, Cooper C 2000 Use of oral corticosteroids in the United Kingdom. Q J Med 99:105-111
3. Truhan A, Ahmed A 1989 Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 62:375-391
4. Adinoff A, Hollister J 1983 Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268
5. Van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C 2000 Use of corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000
6. Reid I, Ibberton H, France J, Pybus J 1985 Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. BMJ 291:574
7. Kamischke A, Kemper D, Castel M, Luthke M, Rolf C, Behre H, Magnussen H, Nieschlag E 1998 Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Resp J 11:41-45
8. Hampson G, Bhargava N, Cheung J, Vaja S, Seed P, Fogelman I 2002 Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. Metabolism 51:1458-1462
9. Eastell R, Reid D, Compston J, Cooper C, Fogelman I, Francis R, Hosking D, Purdie D, Ralston S, Reeve J, Russell R, Stevenson J, Torgerson D 1998 A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 224:271-292
10. Chen S, Wang J, Yu G, Liu W, Pearce D 1997 Androgen and glucocorticoid receptor heterodimer formation. J Biol Chem 272:14087-14092
11. Bhasin S, Storer T, Berman N, Yarasheski K, Clevenger B, Phillips J, Lee W, Bunnell T, Casaburi R 1997 A replacement dose of testosterone increases fat-free mass, and muscle size in hypogonadal men. J Clin Endocrinol Metab 82:407-413
12. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL 2000 Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670-2677
13. Bhasin S, Storer T, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell T, Tricker R, Shirazi A, Casaburi R 1996 The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1-7
14. Bhasin S, Woodhouse L, Storer T 2001 Proof of the effect of testosterone on skeletal muscle. J Endocrinol 170:27-38
15. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E 1998 Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 138:51-58
16. Snyder P, Peachey H, Hannoush P, Berlin J, Loh L, Lenrow D, Holmes J, Dlewati A, Santanna J, Rosen C, Strom B 1999 Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84:2647-2653
17. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie M, Haddad Jr J, Strom B 1999 Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972
18. Russell DW, Berman DM, Bryant JT, Cala KM, Davis DL, Landrum CP, Prihoda JS, Silver RI, Thigpen AE, Wigley WC 1994 The molecular genetics of steroid 5 alpha-reductases. Rec Prog Horm Res 49:275-284
19. Khosla S, Melton 3rd LJ, Riggs BL 2002 Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443-1450
20. Negro-Vilar A 1999 Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 84:3459-3462
21. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA 1993 Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 77:776-779
22. Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E 2001 Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 16:2570-2577
23. Ly L, Handelsman D 2002 Muscle strength and ageing: methodological aspects of isokinetic dynamometry and androgen administration. Clin Exp Pharm Physiol 29:39-47
24. Lips P, Cooper C, Agnusdei F, Caulin F, Egger P, Johnell O, Kanis J, Kellingray S, Leplege A, Liberman U, McCloskey E, Minne H, Reeve J, Reginster J-Y, Scholz M, Todd C, de Vernejoul M, Wiklund I 1999 Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Osteoporos Int 10:150-160
25. Oleksik A, Lips P, Dawson A, Minshall M, Shen W, Cooper C, Kanis J 2000 Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384-1392
26. Barry M, Fowler F, O'Leary M, Bruskewitz R, Holtgrewe H, Mebust W, Cockett A 1992 The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148:1549-1557
27. Hammond G, Nisker J, Jones L, Siiteri P 1980 Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration dialysis. J Biol Chem 255:5023-5026
28. Liang K, Zeger S 1986 Longitudinal data analysis using generalized linear models. Biometrika 73:13-22
29. Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K 2001 Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 56(Suppl 1):24-28
30. Friedl KE, Dettori JR, Hannan CJ, Patience TH, Plymate SR 1991 Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. J Steroid Biochem Mol Biol 40:607-612
31. Hartgens F, Van Marken Lichtenbelt W, Ebbing S, Vollaard N, Rietjens G, Kuipers H 2001 Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration. Int J Sports Med 22:235-241
32. Bross R, Javanbakht M, Bhasin S 1999 Anabolic interventions for aging-associated sarcopenia. J Clin Endocrinol Metab 84:3420-3430
33. Ferreira I, Verreschi I, Nery L, Goldstein R, Zamel N, Brooks D, Jardin J 1998 The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 114:19-28
34. Schols A, Soeters P, Mostert R, Pluymers R, Wouters E 1995 Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. Ant J Respir Crit Care Med 152:1268-1274
35. Demling R, DeSanti L 1997 Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 43:47-51
36. Johansen KL, Mulligan K, Schambelan M 1999 Anabolic effects of nandrolone decanoate in patients receiving dialysis. JAMA 281:1275-1281
37. Handelsman D, Liu P 1998 Androgen therapy in chronic renal failure. Baillieres Clin Endocrinol Metab 12:485-500
38. Reid I, Wattie D, Evan M, Stapleton J 1996 Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1173-1177
39. Horowitz M, Need A, Philcox J, Philcox J, Nordin B 1984 Effect of calcium supplementation on urinary hydroxyproline in osteoporotic postmenopausal women. Am J Clin Nutr 39:857-859
40. Ebeling P, Wark J, Yeung S, Poon C, Salehi N, Nicholson G, Kotowicz M 2001 Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 86:4098-4103
41. Adachi J, Bensen W, Brown J, Hanley D, Hodsman A, Josse R, Kendler D, Lentle B, Olszynski W, Ste-Marie L, Tenenhouse A, Chines A 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
42. Saag K, Emkey R, Schnitzer T 1998 Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299
43. Reid D, Hughes R, Laan R, Sacco-Gibson N, Wenderoth D, Adami S, Eusebio R, Devogelaer J 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial. J Bone Miner Res 15:1006-1020
44. Bergink E, Janssen P, Turpijin E 1985 Comparison of the receptor binding properties of nandrolone and testosterone under in vitro and in vivo conditions. J Steroid Biochem 13:259-267
45. Toth M, Zakar T 1982 Relative binding affinities of testosterone, 19-nortestosterone and their 5 alpha-reduced derivatives to the androgen receptor and to other androgen binding proteins: a suggested role of 5 alpha-reductive steroid metabolism in the dissociation of 'myotropic' and 'androgenic' activities of 19-nortestosterone. J Steroid Biochem 17:653-660
46. Lemus A, Enriquez J, Garcia G, Grillasca I, Perez-Palacios G 1997 5 Alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency. J Steroid Biochem Mol Biol 60:121-129
47. Van der Vies J 1985 Implications of basic pharmacology in the therapy with esters of nandrolone. Acta Endocrinol Suppl 271:38-44
48. Teruel J, Aguilera A, Avila C, Ortuno J 1996 Effects of androgen therapy on prostatic markers in hemodialyzed patients. Scand J Urol Nephrol 30:129-131
49. Kumar N, Didolkar A, Monder C, Bardin C, Sundaram K 1992 The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 130:3677-3683
50. Cummings D, Kumar N, Bardin C, Sundaram K, Bremner W 1998 Prostate-sparing effects in primates of the potent androgen 7 alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 83:4212-4219
51. Deslypere J, Vermeulen A 1985 Influence of age on steroid concentration in skin and striated muscle in women and in cardiac muscle and lung tissues in men. J Clin Endocrinol Metab 60:648-653
52. Colvard D, Eriksen E, Keeting P, Wilson E, Lubahn D, French F, Riggs B, Spelsberg T 1989 Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 86:854-857
53. Smith E, Boyd J, Frank G, Takahashi H, Cohen R, Specker B, Williams T, Lubahn D, Korach K 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061
54. Morishima A, Grumbach M, Simpson E, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698
55. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach K, Simpson E 1997 Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91-95
56. Korach K 1994 Insights from the study of animals lacking functional estrogen receptor. Science 266:1524-1527
57. Fisher C, Graves K, Parlow A, Simpson E 1998 Characterisation of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 95:6965-6970
58. Couse J, Korach K 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20:358-417
59. Vanderschueren D, Van Herck E, Suiker A, Visser W, Schot L, Chung K, Lucas R, Einhorn T, Bouillon R 1993 Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res 8:801-809
60. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1:347-357
61. Need A, Nordin B, Chatterton B 1993 Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate. Osteoporos Int Suppl 1:S218-S222
62. Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys A, Cortenraad M 1993 Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas 17:211-219
63. Hamdy R, Moore W, Whalen K, Landy C 1998 Nandrolone decanoate for men with osteoporosis. Am J Ther 5:89-95
64. Marin P, Oden B, Bjorntorp P 1995 Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 80:239-243
65. Marin P, Krotkiewski M, Bjorntorp P 1992 Androgen treatment of middle-aged obese men: effects on metabolism, muscle and adipose tissue. Eur J Intern Med 1:329-336
66. Gold J, High H, Li Y, Michelmore H, Bodsworth N, Finlayson R, Furner V, Allen B, Oliver C 1996 Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 10:745-752
67. Bizzarro A, Valentini G, Martino G, DaPonte A, De Bellis A, Iacono G 1987 Influence of testosterone therapy in clinical and immunological features of autoimmune diseases associated with Klinefelter's syndrome. J Clin Endocrinol Metab 64:32-36
68. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S 1991 Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 34:1-5